explore -WSS

explore

author：comprehensive 2025-10-02 14:22:20 - browse：5924

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Timeline: Key moments in fight for gay rights

hotspot

WSS

Living organ donors deserve priority status for transplants

Can CDC director Mandy Cohen drive consensus in Washington?

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Blood tests recalled over risk of missed heart attack diagnosis

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Argenx drug significantly slows progression of nerve disorder

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Virginia high school admissions case could be legal follow

Can CDC director Mandy Cohen drive consensus in Washington?

Medical records are filled with copy

Does aspartame cause cancer? What new WHO guidance says

Supreme Court strikes down use of affirmative action

Xenotransplantation trials will require adjusting expectations, experts say

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Altering the blood type of lungs raises potential for universal organs for transplants

Novavax promises a turnaround & Lilly roils the obesity market

Inside the rise of 'mukbang' eating videos

hotspot

Reanimated hearts work just as well for transplants, study finds

Can CDC director Mandy Cohen drive consensus in Washington?

Timeline: Key moments in fight for gay rights

Who gets to use the title 'doctor'?

Involuntary treatment for addiction doesn't work

Why police arrested suspected Gilgo Beach killer away from his house

explore

focus

hotspot

entertainment